Initial learnings on KRAS presentations at AACR23
Exploring new approaches to targeting cancer
There was a lot going on in lung, melanoma, renal and colorectal cancer in terms of immunotherapy in Madrid.
Merck announced their Breakthrough therapy designation for Keytruda in lung cancer this morning. What did we learn from the updated data for checkpoint inhibitors in NSCLC at ESMO that was different from ASCO?
Checkpoint inhibitors are looking very promising in advanced gastric cancer
At ESMO 2014, phase 1 clinical trial data in bladder cancer was presented for Pembrolizumab (Merck) and MPDL3280A (Roche/Genentech).
Genentech and NewLink announced a deal to license an IDO inhibitor. What's the impact of this on the IO pipeline?
Posters on new cancer drugs in development with novel targets were presented at ESMO 2014 Congress in Madrid.
Advances in Metastatic Colorectal Cancer may come from new druggable targets according to ESMO 2014 CRC Symposium
How is the ALK+ lung cancer market developing now that there are multiple next generation competitors following on from Xalkori and Zykadia? Check out our analysis of the developing landscape...
At ESMO 2014 Mary-Ellen Taplin, MD (Dana-Farber Cancer Institute) presented the results of the Tokai Pharmaceuticals ARMOR2 clinical trial of galeterone in men with advanced prostate cancer.
Day 3 of the live blog from the ESMO 2014 Cancer Congress in Madrid.
Day 2 Live Blog with news and commentary on what's taking place at the ESMO Cancer Congress in Madrid
ESMO 2014 Cancer Congress data starts to roll out today - throughout the day we'll be updating the blog with initial impressions of data as it's presented.
Most of the abstracts for oral presentations at the forthcoming ESMO cancer congress in Madrid have just been released. This is a preview of some that caught my attention.
There are some interesting science symposia at #ESMO14 in both immunotherapy and targeted therapies. We review what the hot topics are here.
A review of the key poster and poster discussion abstracts on immunotherapy and targeted therapies at ESMO 2014
Update on what to watch out for in immunotherapy at ESMO 2014.
Preview of some important breast cancer trials being presented in Madrid at #ESMO14.
With the recent FDA approval of Pembrolizumab (Keytruda) we can expect melanoma to be a hot topic at ESMO 2014.
Preview of Prostate Cancer oral presentations at ESMO 2014 Cancer Congress in Madrid.
Restricting the freedom of the press and creating a two-tier access to information at major medical meetings such as ESMO 2014 is both pernicious and toxic.
